Lab Tech Support

Lab Tech Support helps scientists and laboratory analysts increase uptime, research & testing all while decreasing maintenance and repair cost of analytical instrumentation. Laboratory Service Provider with 20+ years of experience in mass spectrometry repair, maintenance and support. Whether your are located in the United States, Canada, Mexico, or Europe, our Service Engineers are available 24/7!

nova biologics, inc.

NOVA Biologics, Inc. is a global provider of biologic raw material intermediates to clinical laboratories, research organizations, and pharmaceutical and in-vitro manufacturers. We offer a range of serums and plasma, including disease state and patient sample materials. As well as human and animal-derived products for use in cell culture, IVD, and further manufacture of therapeutic injectable products. Nova Biologics, Inc. is dedicated to providing the highest quality biologic raw material intermediates to our diverse customer base in order to help meet the demanding needs and requirements of their organizations. We are committed to establishing strategic, long-term relationships with our valued customers and partners by providing them with secure procurement of products at competitive prices in a timely manner. Our vision is to continue to facilitate supply and manufacturing partnerships allowing NOVA to expand our product and service capabilities. Our products include diagnostic serums and plasma, human serum albumin, human gamma globulin, disease plasmas, clinical samples, and human and animal-based materials. Nova is the sales representative for Octapharma excipient albumin to the biotech and pharmaceutical industry worldwide.

Servatus Ltd

We are a biopharmaceutical research and production company, based on the Sunshine Coast, Queensland. Established in 2012, we research, develop and produce high-quality, innovative, medical grade biopharmaceuticals based on the latest scientific research. Servatus has two drug research platforms: Engineered proteins for the treatment of autoimmune diseases, and microbial biotherapeutics for the treatment of inflammatory conditions and bacterial infections. Our protein research focuses on improving specific characteristics of existing therapeutic proteins. We carefully select proteins with clear clinical utility, and through rational redesign of key features, we improve bioavailbility and biological potency. We then rapidly clone and express the proteins in amounts suitable for clinical use, thus providing faster, more effective treatment of chronic auto immune diseases, such as rheumatoid arthritis and psoriasis, with fewer undesirable side effects. In parallel with our protein work, we also develop live microbial biotherapeutic treatments for microbiome-associated conditions, including but not limited to inflammatory bowel disease (IBD), arthritis, atopic dermatitis, and gastrointestinal infections (for example, C. diff and H.pylori infections). We utilise bacterial strains that have not been widely employed previously, but have demonstrated bioactive properties in the latest scientific research. These bacteria have been shown to inhibit pathogenic bacterial growth and infection, modulate immune responses, and regulate inflammatory signals. Bacterial candidates are developed to act directly at specific sites to treat specific ailments and diseases. Servatus currently holds patents for numerous microbial biotherapeutics and engineered proteins for autoimmune disease treatments Servatus Ltd derives its name from the patron saint St Servatus, a 4th century churchman and diplomat, who was invoked as a saint for his healing powers for a range of ailments. #biotech

entos pharmaceuticals

Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.

cpgr

The Centre for Proteomic and Genomic Research (CPGR) plays a pivotal role in advancing South Africa’s ambition to emerge as a leading bio-economy in the 21st century. As a pioneering force in OMICS technology encompassing Genomics, Proteomics, and Bioinformatics, CPGR delivers comprehensive solutions to clients, fostering the growth of the biotechnology sector. Integrating cutting-edge OMICS technologies with bio-computational pipelines, CPGR supports projects in the life sciences and biomedical field in South Africa, all managed through an ISO 9001:2015 certified and compliant quality management system. Founded in 2006 through an initiative by the South African Department of Science and Technology (DST; now the Department of Science and Innovation/DSI), CPGR received financial support from the Technology Innovation Agency (TIA) to boost bio-economic development. This involved making capital-intensive and costly-to-maintain capacity accessible to scientists in academia and industry, thereby enhancing their capacity for publishing and patenting. CPGR's OMICS accelerator programs have led to the establishment of Artisan Biomed (established in 2015, now known as Mediclinic Precise) and, more recently, D-CYPHR (2022). Additionally, CPGR hosts DIPLOMICS, a substantial infrastructure program initiated by the DST. Since its inception, CPGR has facilitated over 1 200 OMICS research projects, consistently striving to implement the latest OMICS solutions to enrich the biotechnology sector in South Africa. For more information about CPGR: www.cpgr.org.za Connect with us: linktr.ee/thecpgr